Variables from Bronch-UK/EMBARC Registry | Reported in the survey: type of ACT performed | ||||
Non-adjuncts | Adjuncts | ||||
n | n | p-value (95% CI) | |||
Demographics | |||||
Age years | 43 | 69 (59–74) | 50 | 64 (55–72) | 0.06 (−11.00–0.00006) |
Sex, female | 43 | 21 (49) | 50 | 36 (72) | 0.04 |
Smoking status (Yes) | 43 | 0 (0) | 50 | 2 (2) | 0.01 |
BMI kg·m−2 | 12 | 26 (24–30) | 17 | 23 (22–27) | 0.22 (−5.39–1.49) |
Lung function | |||||
FEV1 L | 16 | 2±1 | 26 | 2±1 | 0.94 (−0.47–0.51) |
FEV1 % predicted | 13 | 95 (62–110) | 18 | 73 (54–97) | 0.25 (−40.09–11.07) |
Mild (> 80%) | 8 (62) | 8 (44) | 0.57 | ||
Moderate–severe (≤80%) | 5 (38) | 10 (56) | |||
Pulmonary exacerbations | |||||
Total exacerbations in the preceding year | 43 | 1 (0–3) | 50 | 2 (1–4) | 0.15 (−0.00003–1.00) |
No exacerbations | 14 (33) | 10 (20) | 0.24 | ||
1–2 exacerbations | 15 (35) | 16 (32) | |||
≥3 exacerbations | 14 (33) | 24 (48) | |||
mMRC | |||||
Overall | 43 | 1 (1–2) | 50 | 1 (1–3) | 0.71 (−0.00007–1.00) |
Grade 0–1 | 8 (19) | 5 (10) | 0.37 | ||
Grade 2–4 | 35 (81) | 45 (90) | |||
Sputum | |||||
Produces daily sputum (Yes) | 43 | 37 (86) | 50 | 45 (90) | 0.79 |
Sputum colour | 37 | 45 | |||
Mucoid | 22 (59) | 22 (49) | 0.24 | ||
Mucopurulent | 7 (19) | 16 (36) | |||
Purulent/severely purulent | 8 (22) | 7 (16) | |||
Sputum volume mL | 37 | 18 (6–30) | 45 | 30 (6–40) | 0.31 (−0.92–12.24) |
Mild (<10 mL) | 11 (30) | 14 (31) | 1 | ||
Moderate-severe (≥10 mL) | 26 (70) | 31 (69) | |||
Pseudomonas aeruginosa (Yes) | 43 | 4 (9) | 50 | 6 (12) | 0.93 |
BSI | 43 | 7 (5–10) | 49 | 8 (5–12) | 0.22 (−1.00–3.00) |
QoL-B domains | |||||
Physical functioning | 39 | 40 (20–70) | 47 | 40 (20–60) | 0.78 (−13.40–13.30) |
Role functioning | 40 | 53 (32–68) | 47 | 47 (33–67) | 0.81 (−13.30–6.70) |
Vitality | 39 | 44 (33–56) | 47 | 44 (22–56) | 0.61 (−11.10–11.10) |
Emotional functioning | 39 | 75 (54–96) | 47 | 75 (50–83) | 0.44 (−16.70–8.30) |
Social functioning | 40 | 46 (24–69) | 47 | 44 (25–67) | 0.75 (−16.60–8.40) |
Treatment burden | 34 | 67 (47–86) | 46 | 56 (36–67) | 0.15 (−22.20–0.00003) |
Health perceptions | 40 | 42 (25–58) | 47 | 42 (17–58) | 0.42 (−16.60–8.30) |
Respiratory symptoms | 40 | 62 (43–78) | 47 | 56 (39–74) | 0.42 (−14.80–7.40) |
Data represent patients who had linked outcome data from the Bronch-UK/EMBARC Registry within 6 months of survey completion (n=108 out of 205#). Data are presented as n (%), mean±sd or median (25–75% interquartile range). ACT: airway clearance treatment; BMI: body mass index; FEV1: forced expiratory volume in 1 s; mMRC: Modified Medical Research Council dyspnoea scale; BSI: bronchiectasis severity index; QoL-B: quality of life – bronchiectasis. #: n=15 out of 108 excluded as they reported they did not perform ACTs.